Recently, the State Drug Administration approved the marketing of amviacridine succinate tablets, a Class 1 innovative drug declared by Tonghua Jinma Pharmaceutical Group Co., Ltd. This medication is a cholinesterase inhibitor used to treat mild to moderate symptoms of Alzheimer's disease. The launch of this drug provides patients with new treatment options.

Recently, the State Drug Administration approved the marketing of amviacridine succinate tablets, a Class 1 innovative drug declared by Tonghua Jinma Pharmaceutical Group Co., Ltd. This medication is a cholinesterase inhibitor used to treat mild to moderate symptoms of Alzheimer's disease. The launch of this drug provides patients with new treatment options.